GH1 and acromegaly: As an example, although the previously described biselective analog, BIM-23244, with selective, potent interaction with both SST2 and 5, yields superior GH suppression, and potentially greater therapeutic benefit for a wider range of patients suffering from acromegaly, the direct suppression of insulin by SST5 raises the potential for unwanted pancreatic side effects.